Timothy Ausink
Physician Assistant · Selah, WANPI 1760902365
Payments from drug & device makers
Across 147 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$730
- AbbVie$633
- Pfizer$399
- Astellas Pharma US Inc$269
- Lilly USA, LLC$144
- Bayer$130
- plus $754 from 14 others
What the payments were for
- Food & beverage$2,82392%
- Education$2368%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $730 |
| AbbVie | 35 | $633 |
| Pfizer | 26 | $399 |
| Astellas Pharma US Inc | 4 | $269 |
| Lilly USA, LLC | 8 | $144 |
| Bayer | 6 | $130 |
| Boehringer Ingelheim | 5 | $115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $106 |
| Exact Sciences | 5 | $101 |
| Johnson & Johnson | 4 | $93 |
| Novo Nordisk | 5 | $75 |
| GSK | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Novartis | 2 | $36 |
| Antares Pharma, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$171
How this compares
$3,059 in reported general payments places this provider in the 90th percentile of 2,741 physician assistant providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $68,982 |
| FarxigaDapagliflozin Propanediol | 60 | $46,609 |
| JardianceEmpagliflozin | 34 | $41,804 |
| EliquisApixaban | 29 | $37,118 |
| TrulicityDulaglutide | 14 | $26,486 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $23,590 |
| EntrestoSacubitril/Valsartan | 13 | $16,460 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $11,470 |
| MyrbetriqMirabegron | 11 | $9,682 |
| BelsomraSuvorexant | 13 | $5,959 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $4,452 |
| Quetiapine Fumarate | 198 | $4,067 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 118 | $3,790 |
| Omeprazole | 290 | $3,701 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $3,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $75 | $68,98271 claims |
| AstraZenecaFarxiga, Nexium | $730 | $50,11573 claims |
| Boehringer IngelheimJardiance | $115 | $41,80434 claims |
| PfizerEliquis | $399 | $37,11829 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $62 | $35,06056 claims |
| Lilly USA, LLCTrulicity | $144 | $26,48614 claims |
| NovartisEntresto | $36 | $16,46013 claims |
| Astellas Pharma US IncMyrbetriq | $269 | $9,68211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,741 physician assistant providers in Washington.
Other physician assistant in Selah
- Jill KandoraShoreline$437K
- Jeannette HartRichland$263K
- Lance KeckTacoma$162K
- Erinn KingSeattle$129K
- Christy VathSeattle$75K
- Scott TaylorMercer Island$71K
- Gina FragioneGraham$69K
- Regan BrownSpokane$56K
- Justin ChapinSeattle$40K
- Susan DuffyBellevue$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.